<!doctype html> <html> <head><style>
             table { border-collapse: collapse; }
             th, td {
               word-wrap: break-word;
               max-width: 100%;
               font-family: "Trebuchet MS", Arial, Helvetica, sans-serif;
               border-bottom: 1px solid #ddd;
               padding: 5px;
               text-align: left;
             }
            tr:hover {background: #f4f4f4;}
            tr:hover .highlighted {background: repeating-linear-gradient(
                    45deg,
                    #ffff99,
                    #ffff99 10px,
                    #f4f4f4 10px,
                    #f4f4f4 20px
                  );}
           .highlighted { background-color: #ffff99; }
          </style></head><body><h2>Alzheimer's disease research</h2><br> <b>Section Title</b>: Disease-modifying drug candidates <br><b>Table Section Text</b>: <i> None </i> <br> <table>
<tr> <th colspan=1 rowspan=1 > Target/Approach </th><th colspan=1 rowspan=1 > Notes (Theoretical) </th><th colspan=1 rowspan=1 > Candidate Name </th><th colspan=1 rowspan=1 > Trial Phase </th><th colspan=1 rowspan=1 > Trial Start Date </th><th colspan=1 rowspan=1 > Expected End Date </th><th colspan=1 rowspan=1 > Planned Enrollment </th><th colspan=1 rowspan=1 > AD population targeted (severity) </th><th colspan=1 rowspan=1 > AD population targeted (genetic) </th><th colspan=1 rowspan=1 > Comments </th></tr>
<tr> <td colspan=9 rowspan=1 > Currently Active </td><td colspan=1 rowspan=1 >  </td></tr>
<tr> <td colspan=1 rowspan=1 > Neuroprotection </td><td colspan=1 rowspan=1 > Neuroprotective Peptide, intra-nasal </td><td colspan=1 rowspan=1 > AL-108 </td><td colspan=1 rowspan=1 > Phase II (completed) </td><td colspan=1 rowspan=1 > Jan 2007 </td><td colspan=1 rowspan=1 > Jan 2008 </td><td colspan=1 rowspan=1 > 120 </td><td colspan=1 rowspan=1 > Mild Cognitive Impairment </td><td colspan=1 rowspan=1 > n/a </td><td colspan=1 rowspan=1 > Deemed a Success; Phase III to start[dubious – discuss] </td></tr>
<tr> <td colspan=1 rowspan=1 > Brain Cell Apoptosis Inhibitor </td><td colspan=1 rowspan=1 > Operates through multiple mechanisms: Blocks the action of neurotoxic beta-amyloid proteins and inhibits L-type calcium channels, modulates the action of AMPA and NMDA glutamate receptors, may exert a neuroprotective effect by blocking a novel target that involves mitochondrial pores, and blocks a number of other receptors, including α-adrenergic, 5-HT2C, 5-HT5A, and 5-HT6 </td><td colspan=1 rowspan=1 > latrepirdine (trade name: Dimebon) </td><td colspan=1 rowspan=1 > Phase II (completed) </td><td colspan=1 rowspan=1 > Sep 2006 </td><td colspan=1 rowspan=1 > Nov 2007 (actual) </td><td colspan=1 rowspan=1 > 183 </td><td colspan=1 rowspan=1 > Mild-to-Moderate </td><td colspan=1 rowspan=1 > n/a </td><td colspan=1 rowspan=1 > In March 2010, Pfizer announced that the Phase III CONNECTION trial failed to meet its primary and secondary endpoints. In January 2012, it was announced that the Phase III CONCERT study did not meet its co-primary endpoints. </td></tr>
<tr> <td colspan=1 rowspan=1 > Natural Antibodies to amyloid beta </td><td colspan=1 rowspan=1 > human plasma source limits supply </td><td colspan=1 rowspan=1 > IVIg </td><td colspan=1 rowspan=1 > Phase II (completed) </td><td colspan=1 rowspan=1 > Feb 2006 </td><td colspan=1 rowspan=1 > June 2007 </td><td colspan=1 rowspan=1 > 24 </td><td colspan=1 rowspan=1 > Mild-to-Moderate </td><td colspan=1 rowspan=1 > n/a </td><td colspan=1 rowspan=1 > Deemed a Success; Phase III to start </td></tr>
<tr> <td colspan=1 rowspan=1 > Vaccine to amyloid beta </td><td colspan=1 rowspan=1 > Injects modified amyloid beta (active vaccine) </td><td colspan=1 rowspan=1 > ACC-001 </td><td colspan=1 rowspan=1 > Phase II </td><td colspan=1 rowspan=1 > Nov 2007 </td><td colspan=1 rowspan=1 > Mar 2012 </td><td colspan=1 rowspan=1 > 228 </td><td colspan=1 rowspan=1 > Mild-to-Moderate </td><td colspan=1 rowspan=1 > n/a </td><td colspan=1 rowspan=1 > Sequel to famous AN-1792 Vaccine Trial </td></tr>
<tr> <td colspan=9 rowspan=1 > Discontinued </td><td colspan=1 rowspan=1 >  </td></tr>
<tr> <td class="highlighted"  colspan=1 rowspan=1 > Gamma Secretase Modulator/NSAID </td><td colspan=1 rowspan=1 > Shifts amyloid beta production to shorter and less toxic species. Targets γ-secretase. </td><td class="highlighted"  colspan=1 rowspan=1 > R-flurbiprofen (Flurizan, MPC-7869) </td><td colspan=1 rowspan=1 > Phase III (completed) </td><td colspan=1 rowspan=1 > Feb 2005 </td><td colspan=1 rowspan=1 > May 2008 </td><td colspan=1 rowspan=1 > 1,600 </td><td colspan=1 rowspan=1 > Mild </td><td colspan=1 rowspan=1 > n/a </td><td colspan=1 rowspan=1 > Myriad Genetics concluded that the drug did not improve thinking ability or the ability of patients to carry out daily activities significantly more than those patients with placebo. </td></tr>
<tr> <td colspan=1 rowspan=1 > Gamma Secretase Inhibitor </td><td colspan=1 rowspan=1 > Inhibits Gamma Secretase, which reduces amyloid beta levels </td><td colspan=1 rowspan=1 > Semagacestat (LY450139) </td><td colspan=1 rowspan=1 > Phase III (completed) </td><td colspan=1 rowspan=1 > Sep 2008 </td><td colspan=1 rowspan=1 > Apr 2011 </td><td colspan=1 rowspan=1 > 1,100 </td><td colspan=1 rowspan=1 > Mild-to-Moderate </td><td colspan=1 rowspan=1 > n/a </td><td colspan=1 rowspan=1 > On August 17, 2010, Eli Lilly announced that it would "halt development of semagacestat" as it "did not slow disease progression and was associated with worsening...cognition and the ability to perform activities of daily living." Also, it is "associated with an increased risk of skin cancer." </td></tr>
<tr> <td colspan=1 rowspan=1 > Antibody to amyloid beta </td><td colspan=1 rowspan=1 > Mimics natural antibody triggered by AN-1792 </td><td colspan=1 rowspan=1 > Bapineuzumab (aab-001) </td><td colspan=1 rowspan=1 > Phase III (completed) </td><td colspan=1 rowspan=1 > Dec 2007 </td><td colspan=1 rowspan=1 > Apr 2012 </td><td colspan=1 rowspan=1 > 1,121 </td><td colspan=1 rowspan=1 > Mild-to-Moderate </td><td colspan=1 rowspan=1 > Apolipoprotein E4 Carriers only </td><td colspan=1 rowspan=1 > On August 6, 2012, Pfizer and Johnson & Johnson said they are "ending development of an intravenous formulation" of bapineuzumab. Phase III trials "showed no treatment effect on either cognitive or functional outcomes. </td></tr>
<tr> <td colspan=1 rowspan=1 > Antibody to amyloid beta </td><td colspan=1 rowspan=1 > Mimics natural antibody triggered by AN-1792 </td><td colspan=1 rowspan=1 > Bapineuzumab (aab-001) </td><td colspan=1 rowspan=1 > Phase III (completed) </td><td colspan=1 rowspan=1 > Dec 2007 </td><td colspan=1 rowspan=1 > Jun 2012 </td><td colspan=1 rowspan=1 > 1,331 </td><td colspan=1 rowspan=1 > Mild-to-Moderate </td><td colspan=1 rowspan=1 > Apolipoprotein E4 Non-Carriers only </td><td colspan=1 rowspan=1 > On August 6, 2012, Pfizer and Johnson & Johnson said they are "ending development of an intravenous formulation" of bapineuzumab. Phase III trials "showed no treatment effect on either cognitive or functional outcomes. </td></tr>
<tr> <td colspan=1 rowspan=1 > Metal-Protein Interaction Attenuation </td><td colspan=1 rowspan=1 > Primary targets are copper and zinc. Removes copper and zinc from cerebrospinal fluid. </td><td colspan=1 rowspan=1 > PBT2 (8-hydroxy quinoline) </td><td colspan=1 rowspan=1 > Phase II (completed) </td><td colspan=1 rowspan=1 > Dec 2006 </td><td colspan=1 rowspan=1 > Dec 2007 </td><td colspan=1 rowspan=1 > 80 </td><td colspan=1 rowspan=1 > Early Alzheimer's disease </td><td colspan=1 rowspan=1 > n/a </td><td colspan=1 rowspan=1 > "Did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains prodromal/mild Alzheimer's disease patients." "No improvement was observed on the secondary endpoints of brain metabolic activity, cognition and function; however, there was a trend towards preserving hippocampal brain volume". </td></tr>
<tr> <td colspan=1 rowspan=1 > Fibrilization of amyloid beta </td><td colspan=1 rowspan=1 > Breaks down neurotoxic fibrils, allowing amyloid peptides to clear the body rather than form amyloid plaques. </td><td colspan=1 rowspan=1 > ELND005 (AZD-103, scyllo-Inositol) </td><td colspan=1 rowspan=1 > Phase II (completed) </td><td colspan=1 rowspan=1 > Dec 2007 </td><td colspan=1 rowspan=1 > May 2010 </td><td colspan=1 rowspan=1 > 353 </td><td colspan=1 rowspan=1 > Mild-to-Moderate </td><td colspan=1 rowspan=1 > n/a </td><td colspan=1 rowspan=1 > Phase I produced encouraging results by August 2007. In December 2009, Elan and Transition jointly reported that the Phase II study has been modified so that only the 250 mg twice daily dose will be continued due to "greater rates of serious adverse events, including nine deaths," in the higher dose groups (1000 mg and 2000 mg dosed twice daily). </td></tr>
</table> <br> <h3>Sentence(s)</h3>1. R-flurbiprofen (MPC-7869) is a gamma secretase modulator. <br> <br><br><b>Categories:</b><br><b>Numerical:</b> Uses math skills for writing the sentence. Uses math operations (addition, subtraction, average, etc.), counting numbers, frequency of items, etc.<br> <b>Commonsense:</b> Uses commonsene knowledge about situations humans encounter in everyday life – physical objects, word meanings, social or physical domains, peoples' intentions, etc.<br> <b>Temporal:</b> When concepts related to time and temporal aspects are required for writing the sentence. Duration, ordering, typical time of events, time differences between events.<br> <b>Table:</b> Writing the sentence requires knowledge from the table except: the highlighted cells, row and column headers, table titles, section titles, section texts.<br> <b>Out of Table:</b> Writing the sentence requires external knowledge that is not present in the table nor common sense. Knowledge about some specific domain comes under this category. </body></html>
